POZEN is a progressive pharmaceutical company focused on transforming the way unmet medical needs are addressed by the healthcare industry. POZEN has successfully developed two self-invented products in two years, receiving FDA approval for both. Utilizing the funding from these milestone/royalty streams, the company is currently creating a portfolio of integrated aspirin therapies designed to reduce aspirin’s GI damage and enable its full power. For more information, visit the company’s Web site at www.pozen.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: